-

05:23:47 PM

LIVE Real Time EVFM Stock Market News

EVFM - Evofem Biosciences Inc

05/06/21 4:01 PM

Nasdaq : EVFM

Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update

Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three-month period ended March 31, 2021.First quarter and recent highlights include:Direct-to-consumer (DTC) marketing campaign launched on

RHEA-AI

neutral

04/28/21 11:00 AM

Nasdaq : EVFM

Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two new data sets from its Phase 3 AMPOWER trial evaluating Phexxi (R) (lactic acid, citric acid, potassium bitartrate) will be presented at the 2021 American College of Obstetricians and

RHEA-AI

neutral

04/22/21 8:00 AM

Nasdaq : EVFM

Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the first quarter ended March 31, 2021 as follows:DateThursday, May 6, 2021Time4:30 p.m. ET (1:30

RHEA-AI

neutral

04/21/21 8:00 AM

Nasdaq : EVFM

Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the company will deliver the keynote address and present two poster presentations on Phexxi (R) (lactic acid, citric acid, potassium bitartrate) at the upcoming NCODA 2021 National Spring Forum, which

RHEA-AI

very positive

03/29/21 4:05 PM

Nasdaq : EVFM

Evofem Biosciences Announces Closing of Public Offering of Common Stock

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at $1.75 per share. Evofem's aggregate gross proceeds from the offering, before deducting

RHEA-AI

neutral

03/24/21 10:00 PM

Nasdaq : EVFM

Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a price to the public of $1.75 per share. The gross proceeds from the offering to Evofem, before deducting the

RHEA-AI

neutral

03/24/21 4:00 PM

Nasdaq : EVFM

Evofem Biosciences Announces Proposed Public Offering of Common Stock

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to offer and sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a

RHEA-AI

neutral

03/17/21 8:00 AM

Nasdaq : EVFM

Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get Phexxi," its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-demand birth control method, Phexxi (R) ( lactic acid, citric acid and potassium

RHEA-AI

neutral

03/16/21 8:00 AM

Nasdaq : EVFM

Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled,

RHEA-AI

neutral

03/04/21 4:00 PM

Nasdaq : EVFM

Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2020."2020 was a year of execution for Evofem, marked by the approval and

RHEA-AI

negative